PTC/SB/08s (06-03.)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Remove

Pages,Columns,Lines where

Under the Paperwork Reduction Act of 1995, no persons are required to resp d to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		
	Filing Date		
	First Named Inventor	Barry	Douglas
	Art Unit		
	Examiner Name		
	Attorney Docket Numb	er	AP094-06

U.S.PATENTS

Initial*	No	Patent Number	Code ¹	Issue D	ate	of cited Document		Relevant Passages or Releva Figures Appear		ant	
	1	4755401	A	1988-07	7-05	Von Kries Offried et al.					
	2	6048282	A	2000-04	4-11	Prevost Jacques J. et al.					
	3	4103866 A 1978-08-01 Eley Carl W									
If you wish to add additional U.S. Patent citation information please click the Add button. Add											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	name of Patentee or Applicant		Releva		Lines where ges or Relev	
	1										
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date	Name of Patentee or Applicant of cited Document		vhere Rele	or Relevant	Ts
	1	3537650	DE		A	1987-04-23	Koller Heinrich				

	Application Number		
	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Barry	Douglas
(Not for submission under 37 CFR 1.99)	Art Unit		
,,	Examiner Name		
	Attorney Docket Numb	er	AP094-06

	2	02/076562	wo	A	2002-10-03	Mayfield Ian Ashley		-
If you wisi	h to a	dd additional Foreigr	n Patent Documer	nt citation	information p	lease click the Add butto	n Add	
			NON-PAT	ENT LITI	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.					Тs		
	1							
If you wish	h to a	dd additional non-pa	itent literature doc	ument ci	tation informat	ion please click the Add	button Add	
			E	XAMINE	R SIGNATUR	Έ		
Examiner	Signa	ature				Date Considered		
*EXAMIN	ER: Ir	nitial if reference con	sidered, whether	or not cit	ation is in conf	ormance with MPEP 609	Draw line through a	

See Kink Codes of USPTO Patent Documents at wear USPTO.QDV or MPEP 961.04. * Enter office that issued the document, by the lockletic code (WIPO Standard ST3.) * For Lapraces patent of counters, the ancidation of the parent or the Empart or surpreceds the sear incurred of the patent counter. (*Ancid of counters by the appropriate symbols as endicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark there if Empirical Insurance in the Counter of the patent counters of the patent cou

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Flang Date Fla

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(4)(c)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David A. Guerra/	Date (YYYY-MM-DD)	2006-05-17
Name/Print	David A. Guerra	Registration Number	46443

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.